The Briefing provides an at-a-glance view of some important developments in the information universe surrounding COVID-19. The views presented here are solely those of ECRI Horizon Scanning and have not been vetted by other stakeholders.

Download this Scan

In the past 2 weeks, 5 studies have been published about pregnancy and COVID-19 that might help increase vaccination rates among pregnant people. COVID-19 vaccination rates in this group are currently lower than among the general population.

In the United States, retrospective evidence shows that vaccination during pregnancy demonstrated no increased risk of preterm birth or small-for-gestational-age birth. Furthering the case for vaccination during pregnancy, Scottish and US studies suggest that unvaccinated women who became infected with SARS CoV-2 were more likely to experience stillbirth, complications, or maternal death compared with vaccinated women.

In addition,  a smaller study showed that infection during pregnancy elicits an immune response in the fetus that can still be measured after birth even though the infant does not have COVID-19. Another small study suggests that breastfeeding is safe. Although SARS-CoV-2 viral RNA was detected in the breastmilk of mothers with recent infection, no sign of infectivity or coronavirus replication was detected.

Meanwhile, as the pandemic continues into its third year, the health care industry continues to explore interventions that might address both physical and mental health needs (see Topics to Watch).

Bebtelovimab (LY-CoV1404) to Treat Mild to Moderate COVID-19

At a Glance

  • Bebtelovimab is a monoclonal antibody therapy being investigated to treat patients with mild to moderate COVID-19. Monoclonal antibodies work by blocking the virus from attaching to and infecting human cells.
  • Mutations in some SARS-CoV-2 virus variants have resulted in total or partial resistance to most of the available monoclonal antibody treatments, prompting a need for new treatments capable of neutralizing the currently circulating variants.
  • Laboratory studies have found that bebtelovimab’s binding and neutralizing activity is unaffected by most mutations in the receptor-binding domain of the COVID-19 spike protein, allowing it to still be effective against variants such as Omicron.
  • The company announced it is pursuing FDA Emergency Use Authorization (EUA) for bebtelovimab in the first quarter of 2022.

Online Single-session Interventions to Treat Mental and Behavioral Health in Adolescents and Young Adults During the COVID-19 Pandemic

At a Glance

  • Online single-session mental health interventions might be an accessible, low-cost means to provide timely mental health care to adolescents and young adults.
  • Several online single-session mental health interventions are under investigation in the United States and internationally to help close the gap in mental health services.
  • Data from an unphased, randomized trial of 2 online, single-session interventions targeting behavioral and cognitive depressive symptoms found that both active interventions increased postintervention agency (ie, the perceived ability to control one's own actions and life circumstances) and reduced depressive symptoms, hopelessness, and restrictive eating at 3 months compared with the supportive control intervention.
  • Another study by the University of Pennsylvania found that a single-session intervention improved secondary control and reduced the perceived negative impact of the COVID-19

Return to the Main Page Download this COVID-19 Scan

Commentary in this COVID-19 Scan reflects preliminary views of ECRI Horizon Scanning and internal ECRI stakeholders.
The information contained in this document has not been vetted by other stakeholders.

We welcome your comments on this Scan. Send them by email to [email protected].

Posted: January 31, 2022

What's Happening at PCORI?

The Patient-Centered Outcomes Research Institute sends weekly emails about opportunities to apply for funding, newly funded research studies and engagement projects, results of our funded research, webinars, and other new information posted on our site.

Subscribe to PCORI Emails


Hand pointing to email icon